PAHC News & Events

Consensus $2.74. Raises FY26 revenue view to $1.45B-$1.5B from $1.43B-$1.48B, consensus $1.47B.

Reports Q2 revenue $373.9M, consensus $355.64M. "This was a strong quarter for us, and I'm really proud of how our teams are executing around the world," stated Jack Bendheim, President and Chief Executive Officer. "We're seeing faster than expected uptake of our newly integrated MFA portfolio, which is already giving our results a real lift. At the same time, our nutritional specialty and vaccine offerings continue to deliver strong, sustained growth across key markets. With this momentum and the progress we're making across the business, we feel confident raising our full year guidance. Even with some of the challenges in the global environment, our people continue to show resilience and stay focused on delivering for our customers. With the strategy we have in place and the dedication of our teams, I feel very good about where we're headed."

Phibro Animal Health Corporation announced a leadership transition that will support the Company's continued growth and long-term strategic direction. At the end of this fiscal year, effective July 1, 2026, Jack Bendheim, current Chairman, Chief Executive Officer and President of Phibro will take on a new managerial role as Executive Chairman and Daniel Bendheim will assume the role of Chief Executive Officer and President of Phibro. Jack Bendheim will continue to serve as the Chairman of the Board of Directors of the Company. "As Phibro continues to evolve and expand, this is the right moment to transition leadership to guide the Company's next chapter," said Jack Bendheim. "Dani brings deep knowledge of our business, strong operational discipline and a global perspective that aligns with the future of our industry. I have full confidence in his ability to lead Phibro forward while maintaining the values, relationships and commitment to animal health that have defined our Company for decades." The Company's full executive leadership team will remain in place and the Company's Board of Directors has expressed its unanimous support for the transition and confidence in the leadership team's ability to execute on the Company's growth strategy. In his new role as Executive Chairman, Jack Bendheim will continue to provide strategic oversight, support Phibro's long-term growth initiatives and work closely with the executive leadership team.